NCT05163041: Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: Nectin-4
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of CD137 targeted therapy; Patients with uncontrolled symptomatic brain metastases

Up ↑